Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Response to Comment on Nunley et al. Clinically Relevant Cognitive Impairment in Middle-Aged Adults With Childhood-Onset Type 1 Diabetes. Diabetes Care 2015;38:1768-1776.

Nunley KA, Ryan CM, Saxton JA, Costacou T, Orchard TJ, Rosano C.

Diabetes Care. 2016 Feb;39(2):e25. doi: 10.2337/dci15-0028. No abstract available.

2.

Genetic Risk Score Predicts Late-Life Cognitive Impairment.

Wollam ME, Weinstein AM, Saxton JA, Morrow L, Snitz B, Fowler NR, Suever Erickson BL, Roecklein KA, Erickson KI.

J Aging Res. 2015;2015:267062. doi: 10.1155/2015/267062. Epub 2015 Aug 23.

3.

Age of Childhood Onset in Type 1 Diabetes and Functional Brain Connectivity in Midlife.

Ryan JP, Aizenstein HJ, Orchard TJ, Ryan CM, Saxton JA, Fine DF, Nunley KA, Rosano C.

Psychosom Med. 2015 Jul-Aug;77(6):622-30. doi: 10.1097/PSY.0000000000000206.

4.

Clinically Relevant Cognitive Impairment in Middle-Aged Adults With Childhood-Onset Type 1 Diabetes.

Nunley KA, Rosano C, Ryan CM, Jennings JR, Aizenstein HJ, Zgibor JC, Costacou T, Boudreau RM, Miller R, Orchard TJ, Saxton JA.

Diabetes Care. 2015 Sep;38(9):1768-76. doi: 10.2337/dc15-0041. Epub 2015 Jul 7.

5.

Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities.

Nebes RD, Snitz BE, Cohen AD, Aizenstein HJ, Saxton JA, Halligan EM, Mathis CA, Price JC, Kamboh MI, Weissfeld LA, Klunk WE.

Neuropsychologia. 2013 Sep;51(11):2202-9. doi: 10.1016/j.neuropsychologia.2013.07.017. Epub 2013 Aug 1.

6.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797. Epub 2013 Apr 17.

7.

Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.

Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, Nebes RD, Saxton JA, Snitz B, Dekosky S, Williamson J, Lopez OL, Price JC, Mathis CA, Klunk WE.

Neuroimage. 2013 May 1;71:207-15. doi: 10.1016/j.neuroimage.2013.01.015. Epub 2013 Jan 24.

8.

Association between Cognitive Decline in Older Adults and Use of Primary Care Physician Services in Pennsylvania.

Fowler NR, Morrow LA, Tu LC, Landsittel DP, Snitz BE, Rodriquez EG, Saxton JA.

J Prim Care Community Health. 2012 Jul 1;3(3):201-9. doi: 10.1177/2150131911434204. Epub 2012 Feb 11.

9.

The greater sensitivity of elderly APOE ε4 carriers to anticholinergic medications is independent of cerebrovascular disease risk.

Nebes RD, Pollock BG, Perera S, Halligan EM, Saxton JA.

Am J Geriatr Pharmacother. 2012 Jun;10(3):185-92. doi: 10.1016/j.amjopharm.2012.03.003. Epub 2012 Apr 24.

10.

Amyloid imaging in dementias with atypical presentation.

Wolk DA, Price JC, Madeira C, Saxton JA, Snitz BE, Lopez OL, Mathis CA, Klunk WE, DeKosky ST.

Alzheimers Dement. 2012 Sep;8(5):389-98. doi: 10.1016/j.jalz.2011.07.003. Epub 2012 Jan 30.

11.

Outcomes of mild cognitive impairment by definition: a population study.

Ganguli M, Snitz BE, Saxton JA, Chang CC, Lee CW, Vander Bilt J, Hughes TF, Loewenstein DA, Unverzagt FW, Petersen RC.

Arch Neurol. 2011 Jun;68(6):761-7. doi: 10.1001/archneurol.2011.101.

12.

Cognitive slowing associated with elevated serum anticholinergic activity in older individuals is decreased by caffeine use.

Nebes RD, Pollock BG, Halligan EM, Houck P, Saxton JA.

Am J Geriatr Psychiatry. 2011 Feb;19(2):169-75. doi: 10.1097/JGP.0b013e3181e4490d.

13.

Temporal stability of receptiveness to clinical research on Alzheimer disease.

Lingler JH, Rubin D, Saxton JA.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24 Suppl:S30-4. doi: 10.1097/WAD.0b013e3181f14ac0.

14.

Cognitive test performance predicts change in functional status at the population level: the MYHAT Project.

Ganguli M, Bilt JV, Lee CW, Snitz BE, Chang CC, Loewenstein DA, Saxton JA.

J Int Neuropsychol Soc. 2010 Sep;16(5):761-70. doi: 10.1017/S1355617710000561. Epub 2010 Jul 8.

15.

Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project.

Ganguli M, Chang CC, Snitz BE, Saxton JA, Vanderbilt J, Lee CW.

Am J Geriatr Psychiatry. 2010 Aug;18(8):674-83. doi: 10.1097/JGP.0b013e3181cdee4f.

16.

Age and education effects and norms on a cognitive test battery from a population-based cohort: the Monongahela-Youghiogheny Healthy Aging Team.

Ganguli M, Snitz BE, Lee CW, Vanderbilt J, Saxton JA, Chang CC.

Aging Ment Health. 2010 Jan;14(1):100-7. doi: 10.1080/13607860903071014.

17.

Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve.

Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE.

J Neurosci. 2009 Nov 25;29(47):14770-8. doi: 10.1523/JNEUROSCI.3669-09.2009.

18.

High medical co-morbidity and family history of dementia is associated with lower cognitive function in older patients.

Morrow LA, Snitz BE, Rodriquez EG, Huber KA, Saxton JA.

Fam Pract. 2009 Oct;26(5):339-43. doi: 10.1093/fampra/cmp047. Epub 2009 Jul 7.

19.

A brief instrument to assess treatment response in the patient with advanced Alzheimer disease.

Schmitt FA, Saxton JA, Xu Y, McRae T, Sun Y, Richardson S, Li H.

Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):377-83. doi: 10.1097/WAD.0b013e3181ac9cc1.

PMID:
19571727
20.

Amyloid imaging in mild cognitive impairment subtypes.

Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST.

Ann Neurol. 2009 May;65(5):557-68. doi: 10.1002/ana.21598. Erratum in: Ann Neurol. 2009 Jul;66(1):123. DeKoskym, Steven T [corrected to De-Kosky, Steven T].

Supplemental Content

Loading ...
Support Center